<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Use of mechanical circulatory support (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCS</z:e>) is a part of today's standard therapy in the treatment of end-stage <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this paper we describe characteristics of Thoratec pVAD device for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCS</z:e>, implantation techniques, as well as the most important advantages and complications of application of the device </plain></SENT>
<SENT sid="2" pm="."><plain>We present a 41-year-old patient with dilatated <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, who was the first recipient ofparacorporeal left ventricular assist device (LVAD) in the Republic of Croatia due to end-stage <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>After heart function recovery the patient was successfully weaned from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCS</z:e> after 130 days of support </plain></SENT>
</text></document>